title: A consensus statement regarding the utilization of BMP in spine surgery.
abstract: Recombinant human bone morphogenetic protein - 2 (rh-BMP-2) was first approved by the United States Food and Drug Administration (FDA) in 2002 for use in anterior lumbar interbody fusions. Since that time, it has been estimated that "off label" use accounts for 85 % of applications. Original, industry sponsored studies demonstrated superior fusion rates with decreased incidence of complications when compared with traditional iliac crest bone graft. These studies have been criticized for potential bias and newer research has detailed potential complications as well as alternative applications. Potential off label uses of rhBMP-2 include: anterior lumbar fusions, single level posterior lumbar fusions, multiple level posterior lumbar fusions, posterior cervical fusions, long deformity fusions, in the presence of vertebral osteomyelitis, and in patients with history of malignancy. A review of the literature related to rhBMP-2 was conducted to evaluate its use for the above-mentioned applications with a special focus on fusion rates, observed complications, and clinical or radiographic outcomes.
authors.affiliation: Department of Orthopedic Surgery, Michigan State University, McLaren Oakland, Pontiac, MI, USA.
authors.forename: Brett
authors.initials: B
authors.lastname: Walker
authors.forename: John
authors.initials: J
authors.lastname: Koerner
authors.forename: Sriram
authors.initials: S
authors.lastname: Sankarayanaryanan
authors.forename: Kris
authors.initials: K
authors.lastname: Radcliff